TFA
CERE

Toth Financial Advisory’s Cerevel Therapeutics Holdings, Inc. Common Stock CERE Stock Holding History

Toth Financial Advisory’s Portfolio CERE Stock Details CERE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-30
Closed -$954 – 859
2023
Q2 		$954 Hold
30
– – ﹤0.01% 731
2023
Q1 		$732 Hold
30
– – ﹤0.01% 764
2022
Q4 		$946 Hold
30
– – ﹤0.01% 668
2022
Q3 		$1K Hold
30
– – ﹤0.01% 732
2022
Q2 		$1K Hold
30
– – ﹤0.01% 683
2022
Q1 		$1K Hold
30
– – ﹤0.01% 700
2021
Q4 		$1K Buy
+30
New +$1.06K ﹤0.01% 730

Other funds holding CERE

BCI
Bain Capital Investors Boston, Massachusetts $3.27B AUM 3.23% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Toth Financial Advisory's CERE Position: Q3 2023 in Review

Toth Financial Advisory sold out of Cerevel Therapeutics Holdings, Inc. Common Stock (CERE) in Q3 2023, closing a stake of 30 shares — an estimated $954 sold.

Toth Financial Advisory first reported a position in CERE in Q4 2021 and held it in 7 quarters. The position peaked at $1K in Q3 2022. 119 funds tracked by Wall St. Rank hold CERE as of Q3 2023.

  • Toth Financial Advisory reported no remaining Cerevel Therapeutics Holdings, Inc. Common Stock position as of Q3 2023 after selling out during the quarter.
  • Toth Financial Advisory sold 30 Cerevel Therapeutics Holdings, Inc. Common Stock shares in Q3 2023, an estimated $954.
  • Toth Financial Advisory first reported a position in Cerevel Therapeutics Holdings, Inc. Common Stock in Q4 2021 and held it in 7 quarters.
  • Toth Financial Advisory's Cerevel Therapeutics Holdings, Inc. Common Stock position peaked at $1K in Q3 2022.
  • 119 funds tracked by Wall St. Rank held Cerevel Therapeutics Holdings, Inc. Common Stock as of Q3 2023.

Based on Toth Financial Advisory's 13F filing for Q3 2023, filed 12 Oct 2023.